68

Nanjing Vazyme Biotech Co Ltd

688105 · SHG · Healthcare / Biotechnology

21.07CNY-1.78 (-7.79%)

Price History

Full chart

Market Stats

Previous Close22.85
Open22.68
Day Range21.00 – 22.84
52-Week Range12.89 – 29.16
Volume9.33M
Market Cap14.08B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.01
Dividend Yield1.84%
Beta0.68
50-Day Avg22.06
200-Day Avg17.35

About

Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real-time PCR (qPCR), one-step RT-PCR/RT-qPCR, nucleic acid electrophoresis, genome editing techniques, isothermal amplification, and instant granules; and cell and protein research reagents. It also provides NGS library preparation reagents, such as DNA sequencing, RNA sequencing, target capture sequencing, epigenetics, magnetic beads, NGS library quantification, and single-cell sequencing; reagents for biomedicine, including mRNA vaccine/drug key components, drug discovery tools, ELISA kits vaccine evaluation reagents, and semaglutide drug key components; instruments, including automated liquid handling workstation, automatic nucleic acid isolation system, real-time fluorescence quantitative PCR system, fluorescence quantimeter, and micro horizontal centrifuge; lab consumables for equipment comprising robotic pipette tips, robotic microwell plates, robotic deep well plates, and 96-well flat-bottom microplates; and monkeypox solutions. It serves research institutions, high-throughput sequencing service providers, molecular diagnostic reagent manufacturers, pharmaceutical companies, vaccine companies, contract research organizations (CROs), hospitals, and medical institutions. The company was founded in 2012 and is headquartered in Nanjing, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Lin Cao Ph.D.
  • Employees3.00K
  • HeadquartersBuilding D2, Nanjing, China, 210033, China
  • Websitehttps://www.vazyme.com

Leadership

  • Mr. Lin Cao Ph.D.Chairman of the Board & GM · b. 1979
  • Mr. Wen Xin BiChief Financial Officer · b. 1976
  • Mr. Guo Yang ZhangEmployee Representative Director · b. 1989
  • Mr. Lijun Zhang Ph.D.Deputy GM & Director · b. 1983
  • Ms. Xiao Mei Hu M.B.A.Deputy GM & Director · b. 1967
  • Mr. Jin HuangBoard Secretary · b. 1991
  • Mr. Xiaoyu XuDeputy General Manager · b. 1984
  • Kai ShenAccounting Supervisor

Financials

Income Statement

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue112.37M170.80M268.38M1.56B1.87B3.57B1.29B1.38B1.38B
Growth (%)-+52.00%+57.13%+482.92%+19.44%+90.99%-63.97%+7.15%-0.00%
Cost of Revenue22.38M30.87M43.45M182.96M389.97M1.39B514.89M437.47M1.42B
Gross Profit89.99M139.94M224.93M1.38B1.48B2.18B771.10M940.43M-40.48M
Gross Margin80.09%81.93%83.81%88.30%79.13%60.98%59.96%68.25%-2.94%
Operating Expense89.99M139.41M200.61M408.47M707.52M1.46B871.28M1.00B-1
Operating Income4.52K526.12K24.32M973.02M771.14M717.49M-100.18M-61.39M-40.48M
Operating Margin0.00%0.31%9.06%62.20%41.27%20.10%-7.79%-4.46%-2.94%
EBITDA2.92M5.75M32.04M974.18M799.66M686.09M18.15M65.46M56.88M
EBITDA Margin2.60%3.37%11.94%62.27%42.79%19.22%1.41%4.75%4.13%
Net Income3.64M1.04M25.79M821.73M678.29M594.25M-70.96M-18.09M-16.97M
Net Income Margin3.24%0.61%9.61%52.52%36.30%16.65%-5.52%-1.31%-1.23%
R&D26.28M53.00M62.30M125.53M230.32M396.11M338.62M303.41M280.67M
R&D as % of Total Revenue23.39%31.03%23.21%8.02%12.33%11.10%26.33%22.02%20.37%
Interest Expense298.14K944.03K462.03K1.19M3.96M13.33M36.21M28.26M24.17M
Interest Expense % of Total Revenue0.27%0.55%0.17%0.08%0.21%0.37%2.82%2.05%1.75%

Balance Sheet

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets188.40M250.75M324.33M1.61B4.61B6.01B5.75B5.05B5.03B
Total Liabilities37.57M84.67M124.31M279.28M479.83M1.39B1.72B1.11B1.24B
Total Equity150.82M166.08M200.02M1.33B4.13B4.61B4.03B3.95B3.80B
Cash88.80M83.28M93.77M221.60M1.48B1.54B1.97B434.25M804.90M
Total Debt5.54M31.16M35.69M1.15M91.18M458.14M1.29B694.68M-
Net Debt-83.26M-52.12M-58.08M-220.45M-1.39B-1.09B-679.87M260.44M-

Cash Flow

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-3.86M-4.00M15.20M803.55M616.80M735.17M198.40M-9.68M233.16M
Investing Cash Flow21.88M-56.23M12.19M-933.03M-1.43B-952.44M-900.65M375.21M-
Financing Cash Flow429.36K32.69M5.07M261.20M2.07B79.05M249.80M-786.27M-
Capital Expenditure18.82M32.13M19.88M152.54M261.96M962.86M232.90M74.90M47.39M
Free Cash Flow-22.68M-36.13M-4.68M651.01M354.84M-227.69M-79.91M-84.58M185.77M
Dividends Paid290.77K868.46K1.25M1.45M4.45M120.00M500.01M80.36M77.46M
FCF to OCF587.56%903.48%-30.78%81.02%57.53%-30.97%-40.28%873.59%79.68%
Dividend Paid to FCF-1.28%-2.40%-26.79%0.22%1.25%-52.70%-625.69%-95.02%41.70%

Earnings

Report DateFeb 25, 2022Apr 21, 2022Aug 25, 2022Oct 28, 2022Dec 31, 2022Apr 26, 2023Aug 29, 2023Oct 27, 2023Feb 28, 2024
EPS Estimate-----0.29-0.290.170.18-
EPS Actual0.321.080.460.34-0.38-0.38-0.070.010.01
Surprise-----31.03%-31.03%-141.18%-94.44%-
TimingAfter-hoursPre-marketPre-marketAfter-hours-Pre-marketPre-marketAfter-hoursPre-market

Key Statistics & Ratios

Market Cap14.08B
Enterprise Value12.42B
Trailing P/E0.00
Forward P/E0.00
Price / Sales9.57
Price / Book3.95
EPS-0.01
Book Value6.98
Revenue (TTM)1.47B
Gross Profit (TTM)980.46M
EBITDA-5.44M
Profit Margin-0.60%
Operating Margin-5.06%
Return on Equity-0.50%
Return on Assets-1.20%
Shares Outstanding516.99M
Shares Float175.86M
Beta0.68
Dividend Yield1.84%
Dividend Rate0.50
Payout Ratio166.67%

Dividends

20261×
0.50Jun 3, 2026
20251×
0.12Jun 5, 2025
20242×
0.02Dec 20, 20240.08Jul 8, 2024
20231×
0.96Jun 7, 2023
20221×
0.23Jun 7, 2022

Stock Splits

  • Jun 3, 20261.3:1